Biodexa Secures $3 Million Grant to Support eRapa Program
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage biopharmaceutical company specializing in innovative therapies for unmet medical needs, has recently announced that its collaboration partner, Emtora Biosciences, has been awarded a $3.0 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This funding boosts the total support for their eRapa Phase 3 program focused on familial adenomatous polyposis (FAP) to an impressive $20 million.
Significance of the Grant
Stephen Stamp, CEO and CFO of Biodexa, expressed gratitude towards Emtora for their dedication in preparing the grant application and thanked CPRIT for the award. He emphasized that this grant will enhance the capacity of the study by allowing more clinical sites to participate, which will expedite patient recruitment. The intention is clear: to provide treatment options for patients facing limited choices beyond surgical interventions.
Understanding eRapa and Its Role in FAP Treatment
The Phase 3 study involving eRapa is approaching its implementation phase. This clinical trial, designed to be double-blind and placebo-controlled, seeks to enroll 168 patients in a randomized 2:1 ratio of drug to placebo. The expected locations of the clinical trials span approximately 30 sites across both the US and Europe. In the US, LumaBridge in San Antonio will oversee the trials, while Precision for Medicine LLC will manage the European aspect.
FAP: A Critical Medical Challenge
Familial adenomatous polyposis is characterized by the rapid formation of polyps in the colon and/or rectum, typically starting in the mid-teens. At present, there are no approved treatment options for FAP, leaving regular surveillance and surgical resection as the primary modes of management. If untreated, FAP often progresses to colorectal cancer, underscoring the urgent need for effective therapeutic alternatives.
Market Potential and Financial Opportunities
The potential market for treating FAP is substantial. With prevalence estimates suggesting that one in every 10,000 and one in every 37,600 individuals in the US and Europe respectively may be affected, the market opportunity for eRapa is estimated to reach approximately $7.3 billion. This projection factors in the substantial adult populations in these regions and the high annual costs associated with approved treatments for non-biologic orphan disorders.
What is eRapa?
eRapa is a proprietary oral formulation of rapamycin, also known as sirolimus, an mTOR (mammalian Target Of Rapamycin) inhibitor. This compound plays a crucial role in regulating cellular mechanisms like metabolism and growth, which are pivotal during tumor formation. Previous studies have shown that eRapa can effectively reduce polyp burden significantly in patients, with a reported 75% non-progression rate noted during its Phase 2 trials.
Biodexa's Broader Innovations
Biodexa Pharmaceuticals’ commitment to addressing severe medical conditions is evident in its diverse pipeline, which includes not just eRapa but also other innovative treatments. These include tolimidone for type 1 diabetes management and MTX110 targeting aggressive orphan brain cancers. Through advanced drug delivery technologies, Biodexa aims to enhance therapeutic efficacy and patient outcomes.
Concluding Remarks
With the recent CPRIT grant, Biodexa is poised to make significant strides in the realm of cancer treatment, particularly for FAP patients. The company's ambitious focus on delivering novel therapeutic solutions reflects both a commitment to innovation and a profound understanding of patients’ needs.
Frequently Asked Questions
What is the purpose of the $3 million grant awarded to Biodexa?
The grant will help support the eRapa Phase 3 program focused on treating familial adenomatous polyposis (FAP).
What is eRapa?
eRapa is a proprietary oral formulation of rapamycin, an mTOR inhibitor aimed at treating FAP by reducing polyp burden in patients.
How many patients are involved in the eRapa Phase 3 study?
The study plans to enroll 168 patients in a randomized trial.
What are the standard treatment options for FAP?
The current standard care for FAP includes active surveillance and surgical resection, as there are no approved medications available.
What is the market potential for eRapa?
The estimated market opportunity for eRapa in treating FAP is approximately $7.3 billion based on prevalence rates and treatment costs.
